Gulf Pharmaceutical Industries Julphar announces growth plan

20 April 2022

Gulf Pharmaceutical Industries Julphar, one of the largest pharmaceutical companies in the Middle East and Africa, has announced its Strategy 2030 to drive transformation through sustainable growth and deliver enhanced value for all stakeholders.

Strategy 2030 is set to triple Julphar’s revenues via six central growth pillars - “Maximizing Revenue from current Product Portfolio” “New Product Launches,” “Geographical Expansions,” “Strategic Business Initiatives,” “Advanced Specialty Products Initiative”, and “In-Organic Growth Initiatives.”

The new growth strategy embodies Julphar’s aspirations to be the leading pharmaceutical company in the MENA region, recognized with first-to-market products and value-adding medicines. Strategy 2030 is driven by adopting new, cutting-edge technologies across all Julphar’s manufacturing plants.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK